Commercial Activist investor renews its criticism of Novavax PharmaphorumShah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a "destruction in shareholder value."CommercialRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaphorum Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a “destruction in shareholder value.” CommercialRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make HeadwayNext: Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic Related Stories Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs pharminent June 22, 2026 Commercial The first 14 days: How specialty programs set patients up for success pharminent June 22, 2026 Commercial Denali sells FDA voucher for $195M to support neurodegenerative pipeline pharminent June 19, 2026
